Quidel Corporation (QDEL) Receiving Somewhat Favorable News Coverage, Report Shows
News coverage about Quidel Corporation (NASDAQ:QDEL) has been trending somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Quidel Corporation earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.9788667130513 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Quidel Receives FDA Clearance for Its Solana® RSV + hMPV Assay (finance.yahoo.com)
- Quidel Corporation (QDEL) Receives Average Rating of “Buy” from Brokerages (americanbankingnews.com)
- Quidel to Hold Third Quarter 2017 Financial Results … (tmcnet.com)
- Zacks Investment Research Upgrades Quidel Corporation (QDEL) to “Buy” (americanbankingnews.com)
- Quidel to Hold Third Quarter 2017 Financial Results Conference Call on November 1, 2017 (finance.yahoo.com)
Quidel Corporation (QDEL) remained flat at $41.36 during midday trading on Tuesday. 571,457 shares of the stock were exchanged. The firm’s market capitalization is $1.38 billion. The stock has a 50 day moving average price of $40.12 and a 200 day moving average price of $30.67. Quidel Corporation has a 12-month low of $18.25 and a 12-month high of $45.55.
Quidel Corporation (NASDAQ:QDEL) last posted its earnings results on Wednesday, July 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.18). Quidel Corporation had a negative return on equity of 0.03% and a negative net margin of 0.03%. The firm had revenue of $38.30 million for the quarter, compared to analysts’ expectations of $41.91 million. During the same period in the previous year, the company earned ($0.11) earnings per share. The company’s revenue was down 2.0% compared to the same quarter last year. On average, equities analysts anticipate that Quidel Corporation will post $0.29 earnings per share for the current fiscal year.
QDEL has been the topic of a number of recent analyst reports. Zacks Investment Research cut Quidel Corporation from a “hold” rating to a “strong sell” rating in a report on Saturday, July 29th. BidaskClub cut Quidel Corporation from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 16th. William Blair raised Quidel Corporation from a “market perform” rating to an “outperform” rating in a report on Tuesday, July 18th. TheStreet cut Quidel Corporation from a “b-” rating to a “c” rating in a report on Wednesday, July 26th. Finally, Canaccord Genuity reissued a “buy” rating and set a $48.00 price target (up from $42.00) on shares of Quidel Corporation in a report on Tuesday, September 19th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $48.00.
WARNING: “Quidel Corporation (QDEL) Receiving Somewhat Favorable News Coverage, Report Shows” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/17/quidel-corporation-qdel-receiving-somewhat-favorable-news-coverage-report-shows.html.
In related news, CEO Douglas C. Bryant sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, September 27th. The shares were sold at an average price of $42.17, for a total value of $506,040.00. Following the transaction, the chief executive officer now directly owns 296,493 shares of the company’s stock, valued at approximately $12,503,109.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Douglas C. Bryant sold 36,000 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $33.83, for a total transaction of $1,217,880.00. Following the completion of the transaction, the chief executive officer now directly owns 296,493 shares in the company, valued at $10,030,358.19. The disclosure for this sale can be found here. Over the last three months, insiders have sold 227,388 shares of company stock worth $8,274,312. Corporate insiders own 22.00% of the company’s stock.
About Quidel Corporation
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Stock Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related stocks with our FREE daily email newsletter.